The groundbreaking rise of Viagra presented a massive opportunity for investors , but its patent has lapsed , creating a challenging landscape. Generic versions have entered the arena, eroding profits and putting a squeeze on profit percentages . While established pharmaceutical companies maintain a presence in this area, the potential seems unclea